{"id":"W2159967578","doi":"10.1056/nejmoa1209124","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3784,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Trastuzumab emtansine; Trastuzumab; Antibody-drug conjugate; Medicine; Cytotoxic T cell; Metastatic breast cancer; Conjugate; Breast cancer; Oncology; Antibody; Linker; Cancer research; Cancer; Monoclonal antibody; Pharmacology; Internal medicine; Immunology; In vitro; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001252512,0.0002049619,0.0006377842,0.0002286278,0.0001262074,0.0002486735,0.0001820591,0.0002379938,0.00220844],"category_scores_gemma":[0.001269592,0.0000620779,0.0003039495,0.0001897603,0.0001676973,0.0001428885,0.0001751295,0.0004034406,0.0002607927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004541817,"about_ca_system_score_gemma":0.0004450624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001707179,"about_ca_topic_score_gemma":0.0004663772,"domain_scores_codex":[0.9995201,0.0002830489,0.00004914189,0.00004874412,0.00006438853,0.00003466319],"domain_scores_gemma":[0.9996144,0.0001438251,0.000111136,0.00002223551,0.00002960258,0.00007883421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1794291,0.003285172,0.0196005,0.003576882,0.001046056,0.000815886,0.0002049646,0.004192044,0.02989654,0.001285131,0.007085094,0.7495826],"study_design_scores_gemma":[0.3092201,0.2832177,0.141144,0.001833591,0.004356595,0.00910824,0.0002005469,0.009094613,0.04134228,0.005316231,0.1950686,0.00009758649],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517747,0.03665848,0.00184132,0.00168505,0.0002738614,0.001427805,0.0003788438,0.00004560623,0.005914249],"genre_scores_gemma":[0.9864075,0.008929901,0.001537962,0.0006324224,0.0002217745,0.000512834,0.0003384818,0.00000675912,0.001412186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00220844,"threshold_uncertainty_score":0.007387996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0357706020618461,"score_gpt":0.3903459424953969,"score_spread":0.3545753404335508,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}